Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 12/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827436 | 0.90 | DGAT2 (0.47) | NPC1POLBGSK3AGSK3BNTRK1 | |
| SCHEMBL3831198 | 0.87 | NPC1 (0.47) | NPC1RAB9APOLBGSK3AGSK3B | |
| SCHEMBL3833669 | 0.86 | NPC1 (0.58) | NPC1POLBNTRK1DGAT2 | |
| SCHEMBL3832804 | 0.86 | NTRK1 (0.44) | NPC1RAB9APOLBNTRK1DGAT2 | |
| SCHEMBL3831176 | 0.86 | NTRK1 (0.52) | NPC1POLBGSK3AGSK3BNTRK1 | |
| SCHEMBL3830604 | 0.85 | NTRK1 (0.47) | NPC1POLBNTRK1DGAT2 | |
| SCHEMBL27618544 | 0.83 | NPC1 (0.42) | NPC1RAB9APOLBABL1NTRK1 | |
| SCHEMBL27637724 | 0.81 | NPC1 (0.51) | NPC1RAB9AL3MBTL1POLBGSK3A | |
| SCHEMBL1201890 | 0.79 | MAPT (0.50) | NPC1RAB9AL3MBTL1POLBNTRK1 | |
| SCHEMBL1203559 | 0.79 | NPC1 (0.55) | NPC1RAB9APOLBNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460071-B1 | N-HETEROARYLNICOTINAMIDE DERIVATIVES | MITSUI CHEMICALS AGRO INC (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-7015236-B2 | N-heteroarylnicotinamide derivatives | SANKYO AGRO COMPANY, LIMITED (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20050004368-A1 | N-heteroarylnicotinamide derivatives | SANKYO ARGO COMPANY LIMITED (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1460071-A1 | N-HETEROARYLNICOTINAMIDE DERIVATIVES | Sankyo Agro Company, Limited (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004368-A1 | N-heteroarylnicotinamide derivatives | CBR3, CBR1, NAT1 | NPC1 673/4885RAB9A 2134/4885L3MBTL1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.